Positive opinion paves way for third indication in Europe for Kymriah, a potentially definitive single infusion CAR-T cell therapy treatment…
Tapinarof demonstrated continued improvements for up to 52 weeks in efficacy outcomes, quality of life measures, and tolerability scores with…
BASEL, Switzerland, March 25, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical-stage company targeting orphan and large-market central nervous…
- Immunologic response observed in both SARS-CoV-2 naive and previously vaccinated subjects, but lower than expected and inconsistent with known…
MORF-057, an oral α4β7 integrin inhibitor candidate, holds potential for treating inflammatory bowel diseases Phase 2b EMERALD-2 clinical trial of…
Virtual Bio-Europe Spring 2022Kempen Life Sciences Conference Asebio Investor DayMADRID, Spain and CAMBRIDGE, Mass., March 25, 2022 (GLOBE NEWSWIRE) --…
Sub-analysis of the Phase 2b CONTROL study in congenital ichthyosis demonstrates treatment success with TMB-001 regardless of subtype BASKING RIDGE,…
PARSORTIX SHOWS POTENTIAL FOR IDENTIFYING THERAPEUTIC TARGETS IN PATIENTS WITH TRIPLE NEGATIVE BREAST CANCERParsortix system harvests intact CTCs for whole…
Collaboration builds on commitment to advance personalised healthcare by helping to improve access to new treatment options for patients with…
DUBAI, United Arab Emirates, March 25, 2022 /PRNewswire/ -- HSA Group, Yemen ('HSA'), Yemen's largest and leading private company and part…